▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
March 28, 2024

Bio

Celltrion to sell Rituxan biosimilar at 10% discount

  • PUBLISHED :January 24, 2017 - 18:03
  • UPDATED :January 24, 2017 - 18:08
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print

[THE INVESTOR] South Korea’s Celltrion will launch its biosimilar Truxima, referencing Roche’s lymphatic cancer treatment Rituximab, at a 10 percent discount over the price of the branded product in South Korea, according to the company on Jan. 24. 




Truxima is priced at 934,655 won (US$803.80) per 0.5g/50ml. This reflects an approximate 10 percent discount compared to the originator product Roche’s Rituximab of 1,038,506 won when its patent period expires.

According to a Celltrion official, the exact date of Truxima’s launch in Korea is “still under discussion” but industry watchers expect that the knockoff drug will hit pharmacies in the first quarter.

By Park Han-na (hnpark@heraldcorp.com)

EDITOR'S PICKS